Table of Contents

company-logo

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

BioRestorative Therapies Dividend Announcement

• BioRestorative Therapies does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on BioRestorative Therapies dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

BioRestorative Therapies Dividend History

BioRestorative Therapies Dividend Yield

BioRestorative Therapies current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing BioRestorative Therapies stock? Use our calculator to estimate your expected dividend yield:

BioRestorative Therapies Financial Ratios

P/E ratio-2.59
PEG ratio-12.95
P/B ratio1.24
ROE-42.90%
Payout ratio-13.96%
Current ratio2.82
Quick ratio2.82
Cash Ratio0.42

BioRestorative Therapies Dividend FAQ

Does BioRestorative Therapies stock pay dividends?
BioRestorative Therapies does not currently pay dividends to its shareholders.
Has BioRestorative Therapies ever paid a dividend?
No, BioRestorative Therapies has no a history of paying dividends to its shareholders. BioRestorative Therapies is not known for its dividend payments.
Why doesn't BioRestorative Therapies pay dividends?
There are several potential reasons why BioRestorative Therapies would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will BioRestorative Therapies ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While BioRestorative Therapies has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is BioRestorative Therapies a dividend aristocrat?
BioRestorative Therapies is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is BioRestorative Therapies a dividend king?
BioRestorative Therapies is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is BioRestorative Therapies a dividend stock?
No, BioRestorative Therapies is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy BioRestorative Therapies stocks?
To buy BioRestorative Therapies you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy BioRestorative Therapies stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.